N-terminal prohormone brain natriuretic peptide (NT-proBNP) as a noninvasive marker for restrictive syndromes [PDF]
, 2008 Constrictive pericarditis (CP) and restrictive cardiomyopathy share many similarities in both their clinical and hemodynamic characteristics and N-terminal prohormone brain natriuretic peptide (NT-proBNP) is a sensitive marker of cardiac diastolic ...
ARTEAGA, E. +7 more
core +2 more sources
Differentiation of Cardiac from Noncardiac Pleural Effusions in Cats using Second-Generation Quantitative and Point-of-Care NT-proBNP Measurements [PDF]
, 2016 BACKGROUND: Pleural effusion is a common cause of dyspnea in cats. N‐terminal pro‐B‐type natriuretic peptide (NT‐proBNP) measurement, using a first‐generation quantitative ELISA, in plasma and pleural fluid differentiates cardiac from noncardiac causes ...
Boswood, A +7 more
core +2 more sources
Российский кардиологический журнал, 2015 Aim. Assessment of structural and functional condition of the left and right heart chambers related to the level of NT-proBNP and clinical signs of CHD in AH patients.Material and methods.
S. V. Ivanova +4 more
doaj +1 more source
Amino-Terminal Pro-Brain Natriuretic Peptid in Prediction of Left Ventricular Ejection Fraction
Biomolecules & Biomedicine, 2008 We aimed to evaluate levels of amino-terminal pro-brain natriuretic peptid (NT-proBNP) in prediction of left ventricular ejection fraction (LVEF) in heart failure patients.
Mugdim Bajrić +10 more
doaj +1 more source
NT-proBNP and sRAGE levels in early rheumatoid arthritis
Scandinavian Journal of Rheumatology, 2022 Several biomarkers of cardiovascular function are found to be increased in rheumatoid arthritis (RA), with some suggesting a relationship with disease activity and improvement with adequate anti-rheumatic treatment. Promising biomarkers include N-terminal pro-brain natriuretic peptide (NT-proBNP) and the soluble receptor form of advanced glycation end ...
M Heslinga +8 more
openaire +6 more sources
Effects of canagliflozin on cardiovascular biomarkers in older adults with type 2 diabetes [PDF]
, 2017 Background: Sodium glucose co-transporter 2 (SGLT2) inhibitors may reduce cardiovascular and heart failure risk in patients with type 2 diabetes mellitus (T2DM).
Butler, Javed +6 more
core +1 more source
B-type natriuretic peptide versus amino terminal pro-B type natriuretic peptide: selecting the optimal heart failure marker in patients with impaired kidney function [PDF]
, 2013 Background: The effect of impaired kidney function on B-type natriuretic peptide (BNP) and N-terminal proBNP (NT-proBNP) is vague. This study was performed to examine the effect of kidney dysfunction on the afore-mentioned markers and determine ...
Azam, Iqbal +6 more
core +2 more sources
Medicina, 2022 Background and Objectives: N-terminal pro-brain natriuretic peptide (NT-proBNP) is a biomarker used to predict heart failure and evaluate volume status in hemodialysis (HD) patients. However, it is difficult to determine the cutoff value for NT-proBNP in
Kyung Ho Lee +6 more
doaj +1 more source
Rationale and Design of the ICON-RELOADED Study: International Collaborative of Nterminal pro-B-type Natriuretic Peptide Re-evaluation of Acute Diagnostic Cut-Offs in the Emergency Department [PDF]
, 2017 Objectives The objectives were to reassess use of amino-terminal pro B-type natriuretic peptide (NT-proBNP) concentrations for diagnosis and prognosis of acute heart failure (HF) in patients with acute dyspnea.
Chen-Tournoux, Annabel Angela +12 more
core +1 more source
Low NT-proBNP levels in overweight and obese patients do not rule out a diagnosis of heart failure with preserved ejection fraction [PDF]
, 2018 Background Heart failure with preserved ejection fraction (HFpEF) is a heterogeneous syndrome that presents clinicians with a diagnostic challenge. The use of natriuretic peptides to exclude a diagnosis of HFpEF has been proposed.
Abbate, Antonio +9 more
core +1 more source